JPRN-UMIN000011396招募中未知
Eltrombopag treatment for dose-reduction of corticosteroid in corticosteroid dependent adult chronic immune thrombocytopenia (ITP) patients. - Eltrombopag treatment for dose-reduction of corticosteroid in corticosteroid dependent adult chronic immune thrombocytopenia (ITP) patients.
Hematology/ Oncology, Iwate Medical University0 个研究点目标入组 40 人开始时间: 2013年8月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Any history of thrombo-embolic events. 2.Any hereditary disorder that may cause thrombo- embolic events such as ATIII deficiency or Protein C/S deficiency. 3.Any history of allergy/ intolerance to the study drug. 4.Pregnant, possibly pregnant and lactating women as well as women who intend to become pregnant within the proposed study period. 5.Any concomitant drugs or therapy that may influence the result of the study. 6.Renal or hepatic dysfunction/insufficiency. 7. HIV infection, HBV infection 7.Subjects judged as unsuitable for participation in the study for any reason by the physicians in charge of the study. 8.Unable to participate all sessions of the study.
研究者
相似试验
进行中（未招募）
1 期
A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolismIntermediate high-risk acute pulmonary embolismEUCTR2018-000816-96-SIAP-HP/ DRCI650
进行中（未招募）
1 期
A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolismIntermediate high-risk acute pulmonary embolismEUCTR2018-000816-96-FRAP-HP/ DRCI300
进行中（未招募）
1 期
A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolismIntermediate high-risk acute pulmonary embolismEUCTR2018-000816-96-ESAP-HP/ DRCI650
招募中
1 期
A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolismIntermediate high-risk acute pulmonary embolismEUCTR2018-000816-96-NLAP-HP/ DRCI650
进行中（未招募）
1 期
A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolismIntermediate high-risk acute pulmonary embolismEUCTR2018-000816-96-DEAssistance Publique – Hôpitaux de Paris, Clinical Research and Innovation Direction (DRCI)650